GRAIL Reports Q3 2026 Results; Galleri Revenue Rises 14%
Galleri test volume increased about 24% year over year to more than 56,000 in the quarter. The FDA advisory committee voted in favor of approval of GRAIL's Galleri multi-cancer early detection test.
FDA Advisory Committee Voted in Favor of Approval of GRAIL's Galleri Multi-Cancer Early Detection TestQ3 Galleri®Test Volume Increased ~24% to More Than 56,000 Year-Over-Year, Year-to-Date Test Volume Increased ~36% to More Than 174,000Q3 Galleri Revenue Grew 14% Year-Over-Year to $37.3 MillionSUNN…